By selecting ABEC, Lilly aims to capitalise on ABEC's CSR technology for the upstream and downstream processes of the facility, as part of the Basis of Design (BOD) engineering
Eli Lilly Corporate Center, Indianapolis, Indiana, US. (Credit: Momoneymoproblemz/ Wikipedia)
ABEC, a provider of engineered solutions and services for biotech manufacturing, has been chosen by Eli Lilly to supply multiple Custom Single Run (CSR) single-use systems for the latter’s biopharmaceutical manufacturing facility in Limerick, Ireland.
This facility will be built upon ABEC’s advanced CSR single-use technology. The delivery of ABEC’s large-scale CSR Bioreactors, which will serve as the core of the facility, as well as the manufacture, testing, and installation of large-scale CSR GenMix systems, is scheduled for the third quarter of 2023.
By selecting ABEC, Lilly aims to capitalise on ABEC’s CSR technology for the upstream and downstream processes of the facility, as part of the Basis of Design (BOD) engineering.
The BOD effort focused on harnessing the advantages of CSR in terms of scalability, performance, customisation, and supply chain security, aligning with Lilly’s design objectives for the facility.
ABEC’s customised CSR systems will enable Lilly to draw upon their extensive process and operational expertise from their existing plants, facilitating a swift startup, enhanced productivity, seamless technology transfer, and full compliance with regulatory requirements.
The superior mixing and mass transfer capabilities of CSR Bioreactors will support Lilly’s high-density cell culture processes, while the CSR GenMix systems will cater to large-scale harvest and purification needs.
ABEC CEO and chairman Scott Pickering said: “ABEC is proud to be partnering with Lilly on this important project. We are pleased that our unique CSR products and customized, flexible approach will support Lilly’s vision for state-of-the-art manufacturing.”